Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference (FinanzNachrichten) Hemispherx Biopharma, ( Nachrichten ) Inc. (AMEX: HEB), a biopharmaceutical company engaged in the clinical development and manufacture of new drug entities for pandemic disease threats, announced today a new scientific report featuring its antiviral therapeutic product candidate Alferon-LDO in combating highly pathogenic avian influenza (HPAI), also known as “ bird flu. [News Source]